Development of gelatin nanoparticles conjugated with phytohemagglutinin erythroagglutinating loaded with gemcitabine for inducing apoptosis in non-small cell lung cancer cells

NCU Institutional Repository > 生醫理工學院 > 生醫科學與工程學系 > 期刊論文 > Item 987654321/102723

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.lib.ncu.edu.tw/handle/987654321/102723

题名:	Development of gelatin nanoparticles conjugated with phytohemagglutinin erythroagglutinating loaded with gemcitabine for inducing apoptosis in non-small cell lung cancer cells
作者:	陳靖昀;Kuo, Wei-Ting;Huang, Jian-Yuan;Chen, Min-Hua;Chen, Ching-Yun;Shyong, Yan-Jye;Yen, Ko-Chung;Sun, Yu-Jun;Ke, Cherng-Jyh;Cheng, Yung-Hsin;Lin, Feng-Huei
贡献者:	生醫理工學院生醫科學與工程學系
关键词:	adverse effects;Apoptosis;Cancer;caspase-3;caspase-9;Cellular;cytochrome c;cytotoxicity;drug therapy;epidermal growth factor receptors;gelatin;Gelatins;growth retardation;Inhibition;lung neoplasms;Nanoparticles;Nanostructure;neoplasm cells;particle size;Phosphorylation;phytohemagglutinin
日期:	2016-04-14
上传时间:	2026-04-23 11:15:42 (UTC+8)
出版者:	Royal Society of Chemistry;England
摘要:	摘要： Gelatin is an efficient drug delivery vehicle for attaching targeting molecules like phytohemagglutinin erythroagglutinating (PHA-E) and carrying the chemotherapeutic agent gemcitabine (GEM). Fluorescent gelatin nanoparticles (GNPs) conjugated with PHA-E and carrying gemcitabine (GNP-(PHA-E)-GEM) were synthesized by nanoprecipitation for guiding gemcitabine-loaded gelatin nanoparticles to NSCLC by PHA-E targeting. GNPs have a uniform narrow size distribution and spherical shape, and their particle size is about 290 nm. The release rate of gemcitabine from nanoparticles reached the plateau of the curve at approximately 30% within 72 hours. PHA-E conjugated nanoparticles could enhance the cellular accumulation of nanoparticles. The results showed that GNP-(PHA-E)-GEM treatment caused an increase of cell growth inhibition and cytotoxicity on NSCLC cells A-549 and H292. In an Annexin V/PI assay, treatment with GNP-(PHA-E)-GEM could induce apoptosis of cancer cells. Treatment of NSCLC cells with GNP-(PHA-E)-GEM firstly resulted in time-dependent inhibition of epidermal growth factor receptor (EGFR) and Akt phosphorylation. And it also could increase p53 phosphorylation. And then it could decrease Bad phosphorylation and increase Bax. Finally, it could result in enhancing the release of cytochrome c , which thus increases caspase-9 and caspase-3. In conclusion, GNP-(PHA-E)-GEM could induce growth inhibition and cytotoxicity, which was mediated through inhibition of EGFR phosphorylation and the switching on of p53 that causes cell apoptosis of NSCLC cells A-549 and H292. It's significant to conjugate PHA-E for targeting cancer and inhibiting EGFR phosphorylation as it could decrease the dosage of gemcitabine, which reduces side effects on normal tissue. GNP-(PHA-E)-GEM has great potential for NSCLC treatment. Fluorescent gelatin nanoparticles (GNPs) conjugated with PHA-E and carried gemcitabine were synthesized by nanoprecipitation for targeting and treatment of NSCLC cells. 其他題名： J Mater Chem B 出版者： England 出版日期： 2016-04-14 出處： Journal of materials chemistry. B, Materials for biology and medicine, 2016-04, Vol.4 (14), p.2444-2454 資源來源： Royal Society of Chemistry 識別號： ISSN: 2050-750X 識別號： ISSN: 2050-7518 識別號： EISSN: 2050-7518 識別號： DOI: 10.1039/c5tb02598b 識別號： PMID: 32263194
显示于类别:	[生醫科學與工程學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	15	检视/开启

在NCUIR中所有的数据项都受到原著作权保护.

社群 sharing

数据加载中.....